Proteinase inhibitor fusion proteins
CA 2312050 A1 · Owner: Novartis Ag · Inventors: Atkinson, Howard John; Mcpherson, Michael John; Urwin, Peter Edward
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention describes a method of improving pathogen resistance or tolerance in a plant and its descendant plants comprising integrating into the genome of said plant a gene encoding a fusion protein comprising (a) a first protein domain with anti-pathogenic activity; (b) a linker peptide; and (c) a second protein or protein domain with anti-pathogenic activity. Further embodiments of the invention are said gene constructs the fusion proteins encoded and the , transgenic plants expressing said fusion proteins.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 1, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 1, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 1, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.